Human immunodeficiency virus type 1 infection in a community of southern Mozambique. 1991

P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
Istituto di Clinica delle Malattie Infettive dell'Università Cattolica del Sacro Cuore, Roma, Italia.

We report the results of a study held between 1986 and 1988 on a population constituted by 493 subjects (425 of Mozambican nationality) all living in the camp organized for the building of the dam in Corumana (Sabiè district, Maputo). We found five subjects, all of them from Mozambique, seropositive for HIV-1 antibodies (ELISA and WB) with a prevalence of 1.2%. Four of the positive samples came from female subjects (1.7% of 239 females tested); one positive sample came from a male subject (0.5% of 186 tested).

UI MeSH Term Description Entries
D008297 Male Males
D009073 Mozambique A republic in southern Africa, south of TANZANIA, east of ZAMBIA and ZIMBABWE, bordered on the west by the Indian Ocean. Its capital is Maputo. It was formerly called Portuguese East Africa. Portuguese East Africa,Republic of Mozambique
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006679 HIV Seropositivity Development of neutralizing antibodies in individuals who have been exposed to the human immunodeficiency virus (HIV/HTLV-III/LAV). AIDS Seroconversion,AIDS Seropositivity,Anti-HIV Positivity,HIV Antibody Positivity,HIV Seroconversion,HTLV-III Seroconversion,HTLV-III Seropositivity,AIDS Seroconversions,AIDS Seropositivities,Anti HIV Positivity,Anti-HIV Positivities,Antibody Positivities, HIV,Antibody Positivity, HIV,HIV Antibody Positivities,HIV Seroconversions,HIV Seropositivities,HTLV III Seroconversion,HTLV III Seropositivity,HTLV-III Seroconversions,HTLV-III Seropositivities,Positivities, Anti-HIV,Positivities, HIV Antibody,Positivity, Anti-HIV,Positivity, HIV Antibody,Seroconversion, AIDS,Seroconversion, HIV,Seroconversion, HTLV-III,Seroconversions, AIDS,Seroconversions, HIV,Seroconversions, HTLV-III,Seropositivities, AIDS,Seropositivities, HIV,Seropositivities, HTLV-III,Seropositivity, AIDS,Seropositivity, HIV,Seropositivity, HTLV-III
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012423 Rural Health The status of health in rural populations. Health, Rural
D015153 Blotting, Western Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes. Immunoblotting, Western,Western Blotting,Western Immunoblotting,Blot, Western,Immunoblot, Western,Western Blot,Western Immunoblot,Blots, Western,Blottings, Western,Immunoblots, Western,Immunoblottings, Western,Western Blots,Western Blottings,Western Immunoblots,Western Immunoblottings
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human

Related Publications

P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
August 2006, Microbes and infection,
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
June 2005, Current HIV/AIDS reports,
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
July 1998, The New England journal of medicine,
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
October 2022, Infectious diseases & immunity,
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
November 1988, Presse medicale (Paris, France : 1983),
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
January 1995, Annales de dermatologie et de venereologie,
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
November 2017, Biochemical and biophysical research communications,
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
March 2008, AIDS (London, England),
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
January 1995, Nature,
P Mencarini, and A De Luca, and P Ghirga, and F Vichi, and A Antinori, and G Maiuro, and I Noormahomed, and E Tamburrini
August 2005, Clinical and diagnostic laboratory immunology,
Copied contents to your clipboard!